Skip to main content

Drug Interactions between Mavyret and omeprazole

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

omeprazole glecaprevir

Applies to: omeprazole and Mavyret (glecaprevir / pibrentasvir)

MONITOR: Coadministration with omeprazole may decrease the plasma concentrations of glecaprevir. The mechanism of interaction has not been established. When a single 300 mg-120 mg dose of glecaprevir-pibrentasvir was administered with omeprazole 20 mg once daily to 9 study subjects, glecaprevir peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 22% and 29%, respectively. When the dose of glecaprevir-pibrentasvir was administered with omeprazole 40 mg once daily (one hour before glecaprevir-pibrentasvir) to 12 study subjects, glecaprevir Cmax decreased by 64% and AUC decreased by 51%. The pharmacokinetics of pibrentasvir were not affected.

MANAGEMENT: According to the manufacturer, no dosage adjustment is necessary for glecaprevir-pibrentasvir during coadministration with omeprazole. However, the potential for diminished pharmacologic effects of glecaprevir-pibrentasvir should be considered during coadministration with higher dosages of omeprazole. Alternative treatments may be required if an interaction is suspected.

References

  1. (2017) "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical

Switch to consumer interaction data

Drug and food interactions

Moderate

glecaprevir food

Applies to: Mavyret (glecaprevir / pibrentasvir)

ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of glecaprevir and pibrentasvir. Relative to fasting conditions, mean glecaprevir systemic exposure (AUC) increased by 83% to 163% and mean pibrentasvir AUC increased by 40% to 53% when administered with moderate to high fat meals.

MANAGEMENT: Glecaprevir-pibrentasvir should be administered with food.

References

  1. (2017) "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer